{"id":107025,"date":"2025-12-15T17:41:10","date_gmt":"2025-12-15T17:41:10","guid":{"rendered":"https:\/\/www.europesays.com\/se\/107025\/"},"modified":"2025-12-15T17:41:10","modified_gmt":"2025-12-15T17:41:10","slug":"tobii-vinnare-pa-borsen-truecaller-foll-tungt","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/se\/107025\/","title":{"rendered":"Tobii vinnare p\u00e5 b\u00f6rsen \u2013 Truecaller f\u00f6ll tungt"},"content":{"rendered":"<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Utvecklingen i Stockholm speglades av den p\u00e5 ledande europeiska b\u00f6rser. Mest fokus f\u00f6r dagen l\u00e5g vid att <strong>Truecaller<\/strong> varnat f\u00f6r annonsint\u00e4kterna i det fj\u00e4rde kvartalet, samt att <strong>Sobi<\/strong> drog till med ett storf\u00f6rv\u00e4rv.<\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Vid st\u00e4ngningen var OMXS30-indexet upp 0,41% till 2 832,71. Aktier f\u00f6r cirka 20,2 miljarder kronor omsattes p\u00e5 Stockholmsb\u00f6rsen.<\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Bland de ledande aktierna, som ing\u00e5r i OMXS30-index, steg <strong>Boliden<\/strong> 1,9% medan <strong>EQT<\/strong> var upp 1,5%. S\u00e4mst utveckling hade <strong>SKF<\/strong> B med minus 2,0% medan <strong>Handelsbanken<\/strong> A var ned 0,6%.<\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Kommunikationsappen <strong>Truecaller<\/strong> bed\u00f6mer att annonsint\u00e4kterna minskar med cirka 30% till mellan 210 och 230 miljoner kronor under fj\u00e4rde kvartalet, i konstanta valutor. Bolaget flaggar f\u00f6r detta efter att annonsint\u00e4kterna b\u00f6rjat minska fr\u00e5n mitten av augusti, som ett resultat av en f\u00f6r\u00e4ndring i en algoritm hos en av bolagets st\u00f6rsta efterfr\u00e5gepartner och dels en svagare annonsmarknad i Indien. Aktien f\u00f6ll 20,9%.<\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">L\u00e4kemedelsbolaget <strong>Sobi<\/strong> f\u00f6rv\u00e4rvar bioteknikbolaget <strong>Arthrosi Therapeutics<\/strong> f\u00f6r 950 miljoner dollar, motsvarande cirka 9,1 miljarder kronor, i kontanter. D\u00e4rut\u00f6ver kan Sobi beh\u00f6va betala upp till 550 miljoner dollar, motsvarande cirka 5,3 miljoner dollar, i kontanter vid kliniska, regulatoriska och f\u00f6rs\u00e4ljningsrelaterade milstolpar. Aktien f\u00f6ll 1,7%.<\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Massaproducenten <strong>Rottneros<\/strong> vd Lennart Eberleh har sagt upp sig f\u00f6r en annan anst\u00e4llning utanf\u00f6r bolaget. Han l\u00e4mnar sin befattning under f\u00f6rsta halv\u00e5ret 2026. Aktien steg 2,5%.<\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\"><strong>Hansa Biopharma<\/strong> har efter en genomf\u00f6rd \u00f6versyn best\u00e4mt sig f\u00f6r att omorganisera sin europeiska och internationella kommersiella och medicinska verksamhet, och aktien f\u00f6ll 3,9%.<\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Eyetrackingbolaget <strong>Tobii<\/strong> har tecknat ett licensavtal f\u00f6r sin DMS-teknologi med en stor underleverant\u00f6r inom fordonsindustrin. Tobii s\u00e4ger inget om de finansiella detaljerna i avtalet, mer \u00e4n att \u201dv\u00e4rdet p\u00e5 aff\u00e4ren \u00e4r betydande\u201d. Aktien steg 23,6%.<\/p>\n","protected":false},"excerpt":{"rendered":"Utvecklingen i Stockholm speglades av den p\u00e5 ledande europeiska b\u00f6rser. Mest fokus f\u00f6r dagen l\u00e5g vid att Truecaller&hellip;\n","protected":false},"author":2,"featured_media":32452,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[65],"tags":[6171,72,70,71,6459,5822,11950,6309,34,1159,11951,467,31,33,32,30,5879,6091],"class_list":{"0":"post-107025","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-ekonomi","8":"tag-boliden","9":"tag-business","10":"tag-economy","11":"tag-ekonomi","12":"tag-eqt","13":"tag-handelsbanken","14":"tag-hansa-biopharma","15":"tag-rottneros","16":"tag-se","17":"tag-skf","18":"tag-sobi","19":"tag-stockholmsborsen","20":"tag-svenska","21":"tag-sverige","22":"tag-sweden","23":"tag-swedish","24":"tag-tobii","25":"tag-truecaller"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@se\/115724817762598030","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/107025","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=107025"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/107025\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/32452"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=107025"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=107025"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=107025"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}